Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al
J Immunother Cancer
.
2022 Dec;10(12):e006187.
doi: 10.1136/jitc-2022-006187.
Authors
Christopher Grant
#
1
,
Garo Hagopian
#
1
,
Thuy B Tran
2
,
Gayathri Nagaraj
3
,
Justin T Moyers
4
Affiliations
1
Department of Medicine, University of California Irvine, Irvine, California, USA.
2
Division of Surgical Oncology, Department of Surgery, University of California Irvine, Irvine, California, USA.
3
Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, California, USA.
4
Division of Hematology and Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA moyersj@hs.uci.edu.
#
Contributed equally.
PMID:
36600605
PMCID:
PMC9743369
DOI:
10.1136/jitc-2022-006187
No abstract available
Keywords:
Immunotherapy; Melanoma.
Publication types
Letter
Comment
MeSH terms
Humans
Immunotherapy
Melanoma* / therapy